HER 2 Positive Directed Therapies in Metastatic Breast Cancer: Safety and Efficacy Considerations

CME: 0.5

February 22, 2021
/ Print / Reprints /
| Share More
/ Text Size+

Target Audience

Oncologists, oncology nurse practitioners, and oncology physician assistants.

Program Overview

Dr. Hurvitz and Dr Tolaney share key data and expert perspectives on approved and emerging HER-targeted therapies for metastatic breast cancer.

Learning Objectives

Upon completion of this educational activity, learners should be better able to:

  • DESCRIBE the latest clinical advances in HER-directed therapies for advanced or metastatic breast cancer
  • SELECT therapy for advanced or metastatic HER2-positive breast cancer according to the latest evidence and efficacy and safety data
  • DISCUSS available resources for caring for breast cancer patients during a global pandemic

Post a comment to this article